Overview

All Sanguine study protocols and their resulting samples, which include all Sanguine at-home and apheresis collection programs, are conducted under an Institutional Review Board (IRB). Sanguine operates under an electronic informed consent process which executes 21 CFR part 11 compliant e-signatures, and Sanguine systems interacting with study participant information are HIPAA-compliant.

Sanguine’s fresh whole blood collection ensures high-quality, viable samples for research and therapeutic applications. Available in custom volumes with flexible anticoagulant options, our fresh whole blood is ideal for immunology, hematology, and biomarker research.

Well-characterized whole blood for age-related macular degeneration (AMD) research supports studies on inflammation, genetic factors, and therapeutic development to enhance understanding and treatments for this leading cause of vision loss in older adults.